These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 33314600)

  • 1. Comparison of the analytical performance between the Oncomine Dx Target Test and a conventional single gene test for epidermal growth factor receptor mutation in non-small cell lung cancer.
    Sakaguchi T; Iketani A; Furuhashi K; Nakamura Y; Suzuki Y; Ito K; Fujiwara K; Nishii Y; Katsuta K; Taguchi O; Hataji O
    Thorac Cancer; 2021 Feb; 12(4):462-467. PubMed ID: 33314600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive efficacy of low burden EGFR mutation detected by next-generation sequencing on response to EGFR tyrosine kinase inhibitors in non-small-cell lung carcinoma.
    Kim HS; Sung JS; Yang SJ; Kwon NJ; Jin L; Kim ST; Park KH; Shin SW; Kim HK; Kang JH; Kim JO; Park JY; Choi JE; Yoon H; Park CK; Yang KS; Seo JS; Kim YH
    PLoS One; 2013; 8(12):e81975. PubMed ID: 24376508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Feasibility of next-generation sequencing test for patients with advanced NSCLC in clinical practice.
    Ariyasu R; Uchibori K; Ninomiya H; Ogusu S; Tsugitomi R; Manabe R; Sakamaoto H; Tozuka T; Yoshida H; Amino Y; Kitazono S; Yanagitani N; Takeuchi K; Nishio M
    Thorac Cancer; 2021 Feb; 12(4):504-511. PubMed ID: 33350072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical utility of the Oncomine Dx Target Test multi-CDx system and the possibility of utilizing those original sequence data.
    Saito A; Terai H; Kim TJ; Emoto K; Kawano R; Nakamura K; Hayashi H; Takaoka H; Ogata A; Kinoshita K; Ito F; Shigematsu L; Okada M; Fukushima T; Mitsuishi A; Shinozaki T; Ohgino K; Ikemura S; Yasuda H; Kawada I; Soejima K; Nishihara H; Fukunaga K
    Cancer Med; 2024 Feb; 13(4):e7077. PubMed ID: 38457233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical importance of the range of detectable variants between the Oncomine Dx target test and a conventional single-gene test for EGFR mutation.
    Sakaguchi T; Iketani A; Esumi S; Esumi M; Suzuki Y; Ito K; Fujiwara K; Nishii Y; Katsuta K; Yasui H; Taguchi O; Hataji O
    Sci Rep; 2023 Aug; 13(1):13759. PubMed ID: 37612335
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world data on NGS using the Oncomine DxTT for detecting genetic alterations in non-small-cell lung cancer: WJOG13019L.
    Sakata S; Otsubo K; Yoshida H; Ito K; Nakamura A; Teraoka S; Matsumoto N; Shiraishi Y; Haratani K; Tamiya M; Ikeda S; Miura S; Tanizaki J; Omori S; Yoshioka H; Hata A; Yamamoto N; Nakagawa K
    Cancer Sci; 2022 Jan; 113(1):221-228. PubMed ID: 34704312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Possible False Results With cobas
    Kanaoka K; Tamiya A; Inagaki Y; Taniguchi Y; Nakao K; Takeda M; Matsuda Y; Okishio K; Shimizu S
    Anticancer Res; 2023 Jun; 43(6):2771-2776. PubMed ID: 37247929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of next-generation sequencing and cobas EGFR mutation test v2 in detecting EGFR mutations.
    Murakami S; Yokose T; Shinada K; Isaka T; Katakura K; Ushio R; Kondo T; Kato T; Ito H; Saito H
    Thorac Cancer; 2022 Nov; 13(22):3217-3224. PubMed ID: 36203199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ultrasensitive and quantitative detection of EGFR mutations in plasma samples from patients with non-small-cell lung cancer using a dual PNA clamping-mediated LNA-PNA PCR clamp.
    Zhang S; Chen Z; Huang C; Ding C; Li C; Chen J; Zhao J; Miao L
    Analyst; 2019 Feb; 144(5):1718-1724. PubMed ID: 30663747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiple Biomarker Testing Tissue Consumption and Completion Rates With Single-gene Tests and Investigational Use of Oncomine Dx Target Test for Advanced Non-Small-cell Lung Cancer: A Single-center Analysis.
    Yu TM; Morrison C; Gold EJ; Tradonsky A; Layton AJ
    Clin Lung Cancer; 2019 Jan; 20(1):20-29.e8. PubMed ID: 30243889
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive analysis of NGS and ARMS-PCR for detecting EGFR mutations based on 4467 cases of NSCLC patients.
    He C; Wei C; Wen J; Chen S; Chen L; Wu Y; Shen Y; Bai H; Zhang Y; Chen X; Li X
    J Cancer Res Clin Oncol; 2022 Feb; 148(2):321-330. PubMed ID: 34693477
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reliable detection of rare mutations in EGFR gene codon L858 by PNA-LNA PCR clamp in non-small cell lung cancer.
    Skronski M; Chorostowska-Wynimko J; Szczepulska E; Szpechcinski A; Rudzinski P; Orlowski T; Langfort R
    Adv Exp Med Biol; 2013; 756():321-31. PubMed ID: 22836650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison between next-generation sequencing and multiplex polymerase chain reaction assays for nonsmall-cell lung cancer molecular diagnosis.
    Murakami S; Shinada K; Otsutsumi Y; Komine F; Yuan Y; Nakamura J; Katakura S; Kondo T; Kato T; Yokose T; Saito H
    Cancer Med; 2024 Apr; 13(7):e7162. PubMed ID: 38572952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of epidermal growth factor receptor mutation detection turnaround times and concordance among real-time polymerase chain reaction, high-throughput next-generation sequencing and the Biocartis Idylla™ platforms in non-small cell lung carcinomas.
    Sharma S; Satapathy A; Aggarwal A; Dewan A; Jain E; Katara R; Kumar V; Pal R; Pandey S; Naidu MM; Kini L; Pradhan D; Mohanty SK
    Pathol Res Pract; 2021 Apr; 220():153394. PubMed ID: 33706124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of targeted next-generation sequencing with conventional sequencing for predicting the responsiveness to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy in never-smokers with lung adenocarcinoma.
    Han JY; Kim SH; Lee YS; Lee SY; Hwang JA; Kim JY; Yoon SJ; Lee GK
    Lung Cancer; 2014 Aug; 85(2):161-7. PubMed ID: 24857785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EGFR activating mutations detected by different PCR techniques in Caucasian NSCLC patients with CNS metastases: short report.
    Kamila WK; Michał S; Paweł K; Paulina J; Tomasz K; Bożena J; Radosław M; Justyna S; Marek S; Trojanowski T; Janusz M; Joanna CW
    Clin Exp Metastasis; 2013 Dec; 30(8):1063-71. PubMed ID: 23892415
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection and comparison of peptide nucleic acid-mediated real-time polymerase chain reaction clamping and direct gene sequencing for epidermal growth factor receptor mutations in patients with non-small cell lung cancer.
    Kim HJ; Lee KY; Kim YC; Kim KS; Lee SY; Jang TW; Lee MK; Shin KC; Lee GH; Lee JC; Lee JE; Kim SY
    Lung Cancer; 2012 Mar; 75(3):321-5. PubMed ID: 21930325
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utility of Liquid Biopsy by Improved PNA-LNA PCR Clamp Method for Detecting EGFR Mutation at Initial Diagnosis of Non-Small-Cell Lung Cancer: Observational Study of 190 Consecutive Cases in Clinical Practice.
    Ito K; Suzuki Y; Saiki H; Sakaguchi T; Hayashi K; Nishii Y; Watanabe F; Hataji O
    Clin Lung Cancer; 2018 Mar; 19(2):181-190. PubMed ID: 29174086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of diagnostic performance between Oncomine Dx target test and AmoyDx panel for detecting actionable mutations in lung cancer.
    Nagakubo Y; Hirotsu Y; Yoshino M; Amemiya K; Saito R; Kakizaki Y; Tsutsui T; Miyashita Y; Goto T; Omata M
    Sci Rep; 2024 May; 14(1):12480. PubMed ID: 38816489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutation Spectrum of
    Mao L; Zhao W; Li X; Zhang S; Zhou C; Zhou D; Ou X; Xu Y; Tang Y; Ou X; Hu C; Ding X; Luo P; Yu S
    Pathol Oncol Res; 2021; 27():602726. PubMed ID: 34257561
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.